MedTrace Logo

Association of Beta-2 Adrenergic Agonist and Corticosteroid Injection in the Treatment of Lipomas

NCT00624416 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2015-12-21

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to test whether injected medications will increase the amount of fat released by a fat cell. We will compare prednisolone (a synthetic cortisone) combined with isoproterenol (a drug given for asthma) versus using isoproterenol alone. We will also test if injections of isoproterenol and prednisolone will shrink the size of lipomas, which are benign fatty tumors.

Conditions

  • Lipoma

Interventions

DRUG

Prednisolone synthetic cortisone and Isoproterenol together

Approximately 0.2 to 0.4cc of isoproterenol-prednisolone solution (0.04 - 0.08 mg isoproterenol and 0.07 - 0.14 mg prednisolone) in one or more sites in the lipoma depending on its size, 5 days a week for 4 weeks.

Sponsors & Collaborators

  • Lipothera

    collaborator UNKNOWN

  • Pennington Biomedical Research Center

    lead OTHER

Principal Investigators

  • Leanne Redman, Ph.D. · Pennington Biomedical Research Center

  • Frank Greenway, M.D. · Pennington Biomedical Research Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2009-03-31
Completion
2009-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00624416 on ClinicalTrials.gov